| Segment Reporting |
Note
9 – Segment Reporting
We
manage our operations as a 1single segment, focused on advancing the clinical-stage BTKi program and evaluating our legacy pharmaceutical
assets. As our chief operating decision maker, our CEO manages and allocates resources at a consolidated level. He assesses performance,
monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated
statement of operations and comprehensive loss as consolidated net loss.
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and nine months ended September 30, 2026 and 2025 (in thousands):
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,465 |
|
|
$ |
1,204 |
|
|
$ |
3,214 |
|
|
$ |
4,543 |
|
| Research and development personnel expense(1) |
|
|
346 |
|
|
|
458 |
|
|
|
1,056 |
|
|
|
1,154 |
|
| Acquired IPR&D expense |
|
|
178,030 |
|
|
|
- |
|
|
|
178,030 |
|
|
|
- |
|
| General and administrative personnel expense(2) |
|
|
705 |
|
|
|
855 |
|
|
|
1,967 |
|
|
|
2,158 |
|
| Administrative and facilities expense(3) |
|
|
3,583 |
|
|
|
972 |
|
|
|
5,530 |
|
|
|
2,432 |
|
| Other expense, net(4) |
|
|
(972 |
) |
|
|
(52 |
) |
|
|
3 |
|
|
|
(82 |
) |
| Total |
|
$ |
183,157 |
|
|
$ |
3,437 |
|
|
$ |
189,800 |
|
|
$ |
10,205 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $57 and $110 for the three months ended September 30, 2026 and 2025, respectively, and $92 and $166 for the nine months ended September 30, 2026 and 2025, respectively. |
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $182 and $193 for the three months ended
September 30, 2026 and 2025, respectively, and $283 and $438 for the nine months ended September 30, 2026 and 2025, respectively,
and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative & facilities expense primarily consists
of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs. |
| (4) |
|
Other
income, net consists of interest and dividend income, realized and unrealized losses on our digital assets, and other miscellaneous
income. |
|